title: [Basiliximab in the treatment of acute steroid-resistant rejection after liver transplantation].
abstract: We present the case of a liver transplant recipient with alcoholic liver cirrhosis and early-stage hepatocellular carcinoma who developed biopsy-proven acute steroid-resistant rejection 3 months after liver transplantation. After the failure of immunosuppressive therapy with intravenous boluses of 6-methyl-prednisolone and switching of the immunosuppressive regimen to tacrolimus plus mycophenolate mofetil, two doses of intravenous basiliximab were administered four days apart. Clinical, analytical, and biopsy-proven histological response was complete. No basiliximab-related adverse events were detected. Basiliximab may represent an alternative in liver transplantation immunosuppression to treat acute steroid-resistant rejection, without increasing the incidence of infections, neoplasms, or other adverse events, as shown by this case.
authors: Unidad de Trasplantes Abdominales, Hospital Clínico Universitario de Santiago, Santiago de Compostela, España.
authors: Ana M
authors: AM
authors: Alvarez Castro
authors: Susana
authors: S
authors: Seijo Ríos
authors: Esther
authors: E
authors: Molina Pérez
authors: Javier F
authors: JF
authors: Castroagudín
authors: Evaristo
authors: E
authors: Varo Pérez
mesh_terms: D000208:Acute Disease; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000601:surgery; D016572:Cyclosporine / Q000627:therapeutic use; D004351:Drug Resistance; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008104:Liver Cirrhosis, Alcoholic / Q000150:complications / Q000601:surgery; D008111:Liver Function Tests; D008113:Liver Neoplasms / Q000150:complications / Q000601:surgery; D016031:Liver Transplantation; D008297:Male; D008775:Methylprednisolone / Q000494:pharmacology / Q000627:therapeutic use; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D011282:Pregnenediones / Q000494:pharmacology / Q000627:therapeutic use; D015375:Receptors, Interleukin-2 / Q000037:antagonists & inhibitors / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D016559:Tacrolimus / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011282:Pregnenediones; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; D016572:Cyclosporine; D000077552:Basiliximab; D009173:Mycophenolic Acid; C021988:deflazacort; D016559:Tacrolimus; D008775:Methylprednisolone